Wall Street brokerages expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to announce sales of $286.27 million for the current quarter, according to Zacks. Six analysts have made estimates for Integra LifeSciences Holdings Corporation’s earnings. The highest sales estimate is $287.50 million and the lowest is $284.60 million. Integra LifeSciences Holdings Corporation reported sales of $250.33 million during the same quarter last year, which would suggest a positive year over year growth rate of 14.4%. The business is scheduled to announce its next quarterly earnings results before the market opens on Thursday, October 26th.

On average, analysts expect that Integra LifeSciences Holdings Corporation will report full year sales of $286.27 million for the current fiscal year, with estimates ranging from $1.19 billion to $1.20 billion. For the next financial year, analysts expect that the firm will post sales of $1.52 billion per share, with estimates ranging from $1.51 billion to $1.55 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting analysts’ consensus estimates of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same period in the previous year, the business posted $0.40 earnings per share. The business’s revenue for the quarter was up 13.2% on a year-over-year basis.

A number of analysts have commented on IART shares. Zacks Investment Research upgraded Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $57.00 target price on the stock in a research report on Tuesday, October 3rd. Barclays PLC reiterated an “equal weight” rating and set a $53.00 target price (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. Jefferies Group LLC reiterated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. BidaskClub downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Finally, Cantor Fitzgerald started coverage on Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They set an “overweight” rating and a $65.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $54.27.

TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/24/integra-lifesciences-holdings-corporation-iart-expected-to-announce-quarterly-sales-of-286-27-million.html.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. bought 2,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Thursday, August 3rd. The shares were purchased at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the transaction, the director now owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Barbara B. Hill bought 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, August 1st. The shares were acquired at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the transaction, the director now directly owns 44,772 shares of the company’s stock, valued at approximately $2,208,602.76. The disclosure for this purchase can be found here. Insiders have purchased 17,550 shares of company stock worth $864,842 over the last quarter. 21.50% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC lifted its position in Integra LifeSciences Holdings Corporation by 280.0% during the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock worth $104,000 after buying an additional 1,400 shares during the period. Riverhead Capital Management LLC lifted its position in Integra LifeSciences Holdings Corporation by 49.9% during the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock worth $131,000 after buying an additional 799 shares during the period. LS Investment Advisors LLC lifted its position in Integra LifeSciences Holdings Corporation by 4.6% during the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock worth $138,000 after buying an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Integra LifeSciences Holdings Corporation by 8.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after buying an additional 218 shares during the period. Finally, San Francisco Sentry Investment Group CA purchased a new position in Integra LifeSciences Holdings Corporation during the second quarter worth about $174,000. Hedge funds and other institutional investors own 84.90% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) traded down 1.26% during mid-day trading on Tuesday, hitting $50.85. 279,309 shares of the stock were exchanged. The stock has a 50-day moving average price of $50.65 and a 200 day moving average price of $49.89. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of 62.01 and a beta of 0.72.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.